Edgewise Therapeutics Inc Sustainability Reports
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe muscle and cardiovascular disorders. The company specializes in creating orally administered precision small molecule medicines that modulate myosin biology.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00K4Y2H33
3 reports from 2021 to 2024
Company Profile
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe muscle and cardiovascular disorders. The company specializes in creating orally administered precision small molecule medicines that modulate myosin biology.
Reports
3 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
